Pharmaceutical company focusing on identifying and developing psychedelic drugs beyond mental health Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced having entered into a partnership with researchers from University of Wisconsin-Madison.
The researchers namely; Dr. Christopher Nicholas and Dr. Paul Hutson, will support the clinical pharmacology study being conducted by Tryp Therapeutics on its proprietary drug product TRP-8803.
Dr. Hutson is a Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy. He carries with him immense experience when it comes to the medical field concerned with therapeutic uses of psilocybin and other psychoactive compounds.
Dr.Hutson is also the Director of the University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances in the University of Wisconsin School of Pharmacy.
The two doctors, will serve as investigators on clinical pharmacology study to find out the safety and pharmacokinetics of TRP-8803 in healthy, volunteer patients.
“I am excited to work with Tryp to assess the unique features of their proprietary drug product, TRP-8803. Psilocybin-based treatments have incredible clinical potential. Our collaboration will explore important safety and dosing considerations with the potential to create a best-in-class psychedelic therapy with significant benefits to patients across a wide range of indications,” said Dr. Hutson.
On the other side, Dr. Nicolas is an assistant professor at the University of Wisconsin School of Medicine and Public Health in which he also serves as a principal investigator during multiple psilocybin clinical trials.
After the study has been concluded, it will provide more reasons for regulatory support for TRP-8803 as well as insight into the pharmacokinetic profile of TRP-8803.
